Combined pain self-management and antidepressant therapy are effective in patients with chronic musculoskeletal pain with depression  by Hush, Julia
Australian Journal of Physiotherapy 2009  Vol. 55  –   © Australian Physiotherapy Association 2009208
Appraisal Critically Appraised Papers
Summary of: Kroenke K, Bair MJ, Damush TM, Wu J, Hoke 
S, Sutherland J, Tu W (2009) Optimized antidepressant 
therapy and pain self-management in primary care patients 
with depression and musculoskeletal pain; a randomized 
controlled trial. JAMA 301: 2099–2110. [Prepared by Mark 
Elkins, CAP Editor.]
Question: Does a combination of pain self-management 
and antidepressant therapy improve pain and depression in 
people with musculoskeletal pain and depression? Design: 
Randomised, controlled trial with concealed allocation 
and blinded outcome assessment. Setting: Six primary 
care clinics and five tertiary outpatient clinics in the USA. 
Participants: Primary care patients were eligible if they 
had at least moderate pain in the low back, hip, or knee, 
present for at least 3 months despite analgesic medication, 
and depression of at least moderate severity. People taking 
antidepressants but who still met the inclusion criteria were 
eligible. Severe cognitive impairment, major psychoses, 
and current pain-related disability claims were exclusion 
criteria. Randomisation of 250 participants allotted 123 to an 
intervention group and 127 to a control group. Interventions: 
The intervention group participated in the Stepped Care for 
Affective Disorders and Musculoskeletal Pain (SCAMP) 
program. During the initial 3 months (Step 1), this group 
optimised their antidepressant medication according to 
an algorithm based on clinical response, with a potential 
increased dose at 3 weeks and change of medication at 6 
weeks for those who had not improved. During the following 
3 months (Step 2), fortnightly pain self-management sessions 
were conducted by a nurse care manager, modelled on the 
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Stanford self-management program. Participants were 
taught to modify their behaviour through behavioural plans 
and problem-solving techniques. During the final 6 months 
(Step 3), two telephone calls from the nurse care manager 
were used to assess symptoms and adherence, and to adjust 
management if required. The control group were informed 
that they had depressive symptoms and that they should seek 
advice about treatment, but received no other intervention 
unless a psychiatric emergency arose. Outcome measures: 
The primary outcome was a combined improvement in both 
depression and pain. Depression was assessed using the 20-
item Hopkins Symptom Checklist and pain severity using 
the Brief Pain Inventory. Global improvement in pain was 
also assessed. Results: 205 (82%) participants completed 
the final assessment. At 12 months, 26% of the intervention 
group achieved the primary outcome, compared with 8% of 
the control group (RR 3.3, 95% CI 1.8 to 5.4). For depression 
specifically, 37% of the intervention group had a 50% or 
greater reduction in depression severity from baseline 
compared with 16% of the control group (RR 2.3, 95% CI 
1.5 to 3.2). When expressed in terms of major depression, 
41% of the intervention group had major depression at 12 
months compared to 68% of the control group (RR 0.6, 95% 
CI 0.4 to 0.8). A reduction in pain of at least 30% was more 
likely in the intervention group (41%) than the control group 
(17%) (RR 2.4, 95% CI 1.6 to 3.2). Global improvement in 
pain also significantly improved. Conclusion: Combined 
pain self-management and antidepressant medication 
result in substantial improvement in depression as well as 
moderate reductions in pain severity and disability.
Commentary
Over 6 000 000 Australians suffer from musculoskeletal 
conditions such as low back pain, knee, and hip pain 
(ABS 2006). Over twice that number report some level 
of psychological distress, the most commonly reported 
problems being mood disorders such as depression (ABS 
2006). Musculoskeletal pain and depression frequently 
coexist, impacting on health outcomes, disability, and quality 
of life (Bair et al 2003). For primary care practitioners, 
treatment of patients with co-morbid pain and depression 
presents a challenge and treatments do not always result in 
clinically worthwhile benefits for patients.
This clinical trial represents a significant step forward to 
address this dilemma. The authors investigated the long-
term outcomes of a combination of pharmacological and 
behavioural interventions in primary care patients with 
musculoskeletal pain and co-morbid depression. The 
evaluation of the synergistic effects of these two treatments 
in this patient group is novel. The design, conduct, and 
analysis of the trial were robust. The investigators found 
that optimised antidepressant therapy followed by a self-
management program resulted in substantial reductions in 
the severity of depression. The combined intervention also 
produced clinically significant improvements in pain, which 
is impressive in this patient group with musculoskeletal pain 
of long duration (up to 20 years).
The Stepped Care for Affective Disorders and 
Musculoskeletal Pain (SCAMP) program was evaluated in 
North America and implemented by a nurse care manager, 
under the supervision of a physician depression specialist. 
It would be valuable to trial this inter-disciplinary primary 
care program in Australia, in which physiotherapists with 
expertise in cognitive-behavioural approaches to pain 
management could play a prominent role. If found to be 
equally effective in the Australian health care setting, the 
establishment of this program for co-morbid musculoskeletal 
pain and depression has the potential to substantially reduce 
the burden on primary care practitioners and enhance long 
term patient outcomes.
Julia Hush
The University of Sydney
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